L Torres-Collado1,2, M Garcia-de-la-Hera1,2, E M Navarrete-Muñoz1,2, L Notario-Barandiaran1,2, S Gonzalez-Palacios1,2, O Zurriaga2,3,4, I Melchor5,6, Jesus Vioque7,8. 1. Department of Public Health, History of Medicine, and Gynecology, University Miguel Hernández, Alicante Institute for Health and Biomedical Research, ISABIAL-FISABIO Foundation, Ctra. Nacional 332 s/n. Sant Joan d'Alacant, 03550, Alicante, Spain. 2. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain. 3. Dirección General de Salud Pública, Conselleria de Sanitat, Valencia, Spain. 4. Fundación para el Fomento de la Investigación Sanitaria, Biomédica (FISABIO), Valencia, Spain. 5. Unidad de Investigación de Análisis de la Mortalidad y Estadísticas Sanitarias, Departamento de Enfermería Comunitaria, Universidad de Alicante, Alicante, Spain. 6. Registro de Mortalidad de la Comunitat Valenciana, Servicio de Estudios Epidemiológicos y Estadísticas Sanitarias, Subdirección General de Epidemiología y Vigilancia de la Salud, Alicante, Spain. 7. Department of Public Health, History of Medicine, and Gynecology, University Miguel Hernández, Alicante Institute for Health and Biomedical Research, ISABIAL-FISABIO Foundation, Ctra. Nacional 332 s/n. Sant Joan d'Alacant, 03550, Alicante, Spain. vioque@umh.es. 8. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain. vioque@umh.es.
Abstract
PURPOSE: The effect of coffee consumption on mortality has been scarcely investigated in the elderly. We assessed the association between coffee consumption and mortality from all-cause, cardiovascular disease (CVD) and cancer, in an elderly population of Spain. METHODS: We studied 903 individuals (511 women) aged 65 years and older from two population-based studies, the EUREYE-Spain study and the Valencia Nutritional Survey. Coffee consumption and diet were assessed using a validated food frequency questionnaire. Information on education, anthropometry, sleeping time, smoking, alcohol intake, physical activity and pre-existing disease was collected at baseline. Deaths were ascertained during a 12-year follow-up period, and Cox proportional hazards regression models were used to estimate adjusted hazard ratios (HR). RESULTS: There were 403 deaths during the 12-year period (40% from CVD), 174 of which occurred during the first 6 years. We observed evidence of a lower CVD mortality among coffee drinkers in the first 6 years of follow-up. Drinkers of ≤1 cup of coffee/day and > 1 cup/day showed lower CVD mortality than non-drinkers of coffee, HR 0.82 (95% CI 0.46-1.44) and HR 0.38 (0.15-0.96), respectively (p trend = 0.04). This association of coffee with CVD mortality attenuated after 12 years of follow-up. No significant association was observed with all-cause or cancer mortality, neither for caffeinated and decaffeinated coffee. CONCLUSIONS: In this study, coffee consumption was associated with lower CVD mortality in elderly. Although this association should be further investigated, coffee consumption appears to be safe for the elderly since no increased mortality was observed in coffee drinkers.
PURPOSE: The effect of coffee consumption on mortality has been scarcely investigated in the elderly. We assessed the association between coffee consumption and mortality from all-cause, cardiovascular disease (CVD) and cancer, in an elderly population of Spain. METHODS: We studied 903 individuals (511 women) aged 65 years and older from two population-based studies, the EUREYE-Spain study and the Valencia Nutritional Survey. Coffee consumption and diet were assessed using a validated food frequency questionnaire. Information on education, anthropometry, sleeping time, smoking, alcohol intake, physical activity and pre-existing disease was collected at baseline. Deaths were ascertained during a 12-year follow-up period, and Cox proportional hazards regression models were used to estimate adjusted hazard ratios (HR). RESULTS: There were 403 deaths during the 12-year period (40% from CVD), 174 of which occurred during the first 6 years. We observed evidence of a lower CVD mortality among coffee drinkers in the first 6 years of follow-up. Drinkers of ≤1 cup of coffee/day and > 1 cup/day showed lower CVD mortality than non-drinkers of coffee, HR 0.82 (95% CI 0.46-1.44) and HR 0.38 (0.15-0.96), respectively (p trend = 0.04). This association of coffee with CVD mortality attenuated after 12 years of follow-up. No significant association was observed with all-cause or cancer mortality, neither for caffeinated and decaffeinated coffee. CONCLUSIONS: In this study, coffee consumption was associated with lower CVD mortality in elderly. Although this association should be further investigated, coffee consumption appears to be safe for the elderly since no increased mortality was observed in coffee drinkers.
Authors: Laura Torres-Collado; Manuela García-de la Hera; Carla Lopes; Laura María Compañ-Gabucio; Alejandro Oncina-Cánovas; Leyre Notario-Barandiaran; Sandra González-Palacios; Jesús Vioque Journal: Front Nutr Date: 2022-08-30